Evidence map›Paper›PMID 40739313›Full record

ArticleScientific reports2025

Association of Hsa_circ_0059511 with the sensitivity of the temozolomide chemotherapeutic treatment in human glioma cells.

Yiming Chen, Pingxin Cheng, Wei Huang, Yajun Jing, Jinye Su, Zanyi Wu, Jiawei Cai

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yiming Chen *Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Pingxin Cheng *Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Wei Huang *Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Yajun JingDepartment of Neurosurgery, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Jinye SuDepartment of Neurosurgery, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Zanyi WuDepartment of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. kirby98@126.com.
Jiawei CaiDepartment of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. 263987192@qq.com.

Funding

Fujian Provincial Natural Science Foundation 2023J01602
6 · The paper itself

Abstract

While surgical resection combined with temozolomide (TMZ) chemotherapy remains the cornerstone of glioma treatment, therapeutic efficacy is significantly limited by intrinsic and acquired TMZ resistance. This study identified elevated expression of circular RNA circ0059511 in TMZ-resistant glioblastoma tissues and delineated its mechanistic role in chemoresistance. Circ0059511 silencing suppressed glioma cell proliferation, clonogenicity, and metastatic potential, as confirmed by Western blotting. These findings were corroborated in subcutaneous xenograft models, where circ0059511 silencing combined with TMZ reduced tumor volume. Mechanistically, circ0059511 functions as a competitive endogenous RNA that sequesters miR-194-5p, thereby derepressing FZD6 translation to sustain chemoresistance. Rescue experiments established the hierarchical regulatory axis: miR-194-5p inhibition and FZD6 ablation partially reversed the TMZ-sensitizing effects of circ0059511 knockdown. Our work unveils the circ0059511/miR-194-5p/FZD6 axis as a central mediator of TMZ resistance in glioblastoma, providing a rationale for combinatorial therapeutic strategies to overcome chemoresistance.

Indexed as

Antineoplastic Agents, AlkylatingBrain NeoplasmsDrug Resistance, NeoplasmGliomaRNA, CircularTemozolomideAnimalsCell Line, TumorCell ProliferationFrizzled ReceptorsGene Expression Regulation, NeoplasticGlioblastomaHumansMiceMice, NudeMicroRNAsAntineoplastic Agents, AlkylatingFrizzled ReceptorsMicroRNAsRNA, CircularTemozolomidecirc0059511GlioblastomamiR-194-5pTemozolomide resistance

Identifiers

PMID40739313
PMCPMC12311012

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.